Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Dominique SPAETH"'
Autor:
Sylvain Manfredi, Marie Dior, Olivier Bouche, Emilie Barbier, Vincent Hautefeuille, Marielle Guillet, Justine Turpin, Vincent Bourgeois, Dall Osto Helene, Romain Desgrippes, Franck Audemar, Yann Molin, Christophe Locher, Thierry Chatellier, Thierry Lecomte, Nathalie Baize, Cedric Lecaille, Dominique Spaeth, Gael Goujon, Come Lepage, David Tougeron, For The Metestomac Investigators/Collaborators
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5341-5351 (2023)
Abstract Background Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junc
Externí odkaz:
https://doaj.org/article/c63cf54191d040b09637705899990774
Autor:
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, Philipp Harter, Florence Joly, Ulrich Canzler, Caroline Truntzer, Olivier Tredan, Clemens Liebrich, Alain Lortholary, Daniel Pissaloux, Alexandra Leary, Jacobus Pfisterer, Alexandre Eeckhoutte, Felix Hilpert, Michel Fabbro, Christophe Caux, Jérôme Alexandre, Aurélie Houlier, Jalid Sehouli, Emilie Sohier, Rainer Kimmig, Bertrand Dubois, Dominique Spaeth, Isabelle Treilleux, Jean-Sébastien Frenel, Uwe Herwig, Olivia Le Saux, Nathalie Bendriss-Vermare, Andreas du Bois
Publikováno v:
Cancers, Vol 14, Iss 5, p 1189 (2022)
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability i
Externí odkaz:
https://doaj.org/article/02b2a1068ff24c5a91d7c2127c4ded1a
Autor:
Candice Hober, Lisa Fredeau, Anne Pham-Ledard, Marouane Boubaya, Florian Herms, Philippe Celerier, François Aubin, Nathalie Beneton, Monica Dinulescu, Arnaud Jannic, Nicolas Meyer, Anne-Bénédicte Duval-Modeste, Laure Cesaire, Ève-Marie Neidhardt, Élodie Archier, Brigitte Dréno, Candice Lesage, Clémence Berthin, Nora Kramkimel, Florent Grange, Julie de Quatrebarbes, Pierre-Emmanuel Stoebner, Nicolas Poulalhon, Jean-Philippe Arnault, Safia Abed, Bertille Bonniaud, Sophie Darras, Valentine Heidelberger, Suzanne Devaux, Marie Moncourier, Laurent Misery, Sandrine Mansard, Maxime Etienne, Florence Brunet-Possenti, Caroline Jacobzone, Romain Lesbazeilles, François Skowron, Julia Sanchez, Stéphanie Catala, Mahtab Samimi, Youssef Tazi, Dominique Spaeth, Caroline Gaudy-Marqueste, Olivier Collard, Raoul Triller, Marc Pracht, Marc Dumas, Lucie Peuvrel, Pierre Combe, Olivier Lauche, Pierre Guillet, Yves Reguerre, Ingrid Kupfer-Bessaguet, David Solub, Amélie Schoeffler, Christophe Bedane, Gaëlle Quéreux, Sophie Dalac, Laurent Mortier, Ève Maubec
Publikováno v:
Cancers, Vol 13, Iss 14, p 3547 (2021)
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemi
Externí odkaz:
https://doaj.org/article/d9295d94cea242f3a1e1c42dd047374a
Autor:
Sylvain, Manfredi, Marie, Dior, Olivier, Bouche, Emilie, Barbier, Vincent, Hautefeuille, Marielle, Guillet, Justine, Turpin, Vincent, Bourgeois, Dall Osto, Helene, Romain, Desgrippes, Franck, Audemar, Yann, Molin, Christophe, Locher, Thierry, Chatellier, Thierry, Lecomte, Nathalie, Baize, Cedric, Lecaille, Dominique, Spaeth, Gael, Goujon, Come, Lepage, David, Tougeron
Publikováno v:
Cancer medicineREFERENCES.
Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are available on the routine daily management of advanced gastric or gastroesophageal junction cancers. We aim
Autor:
François-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Thibault de la Motte Rouge, Renaud Sabatier, Coraline Dubot, Jean-Sébastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Christelle Levy, Marie-Ange Mouret-Reynier, Alain Lortholary, Julien Grenier, Camille Chakiba, Laetitia Stefani, Jérôme Edouard Plaza, Florian Clatot, Luis Teixeira, Véronique D'Hondt, Hélène Vegas, Olfa Derbel, Claire Garnier-Tixidre, Jean-Luc Canon, Barbara Pistilli, Fabrice André, Laurent Arnould, Anne Pradines, Ivan Bièche, Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, Francois-Clement BIDARD, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Thibault DE LA MOTTE ROUGE, Renaud SABATIER, Coraline DUBOT, Jean-Sébastien FRENEL, Jean-Marc FERRERO, Sylvain LADOIRE, Christelle LEVY, Marie-Ange MOURET-REYNIER, Anne-Claire HARDY-BESSARD, Alain LORTHOLARY, Julien GRENIER, Camille CHAKIBA, Laetitia STEFANI, Patrick SOULIE, Jean-Philippe JACQUIN, Jérôme Edouard PLAZA, Florian CLATOT, Luis TEIXEIRA, Véronique D'HONDT, Hélène VEGAS, Olfa DERBEL, Claire GARNIER TIXIDRE, Catherine DELBALDO, Lionel MOREAU, Caroline CHENEAU, Jean-François PAITEL, Chantal BERNARD-MARTY, Dominique SPAETH, Dominique GENET, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence VENAT-BOUVET, Valérie DELECROIX, Adrien MELIS, Hubert ORFEUVRE, Suzanne NGUYEN, Eric LEGOUFFE, Alain ZANNETTI, Romuald LE SCODAN, Nadine DOHOLLOU, Philippe DALIVOUST, Olivier ARSENE, Nathalie MARQUES, Thierry PETIT, Delphine MOLLON, Jérôme DAUBA, Nathalie BONNIN, François MORVAN, Miriam GARDNER, Adina MARTI, Charles-Briac LEVACHE, Emma LACHAIER, Mihaela ACHILLE, Christophe VALMAR, Ryan BOUAITA, Jacques MEDIONI, Cyril FOA, Francesco DEL PIANO, Michel GOZY, Anne ESCANDE, Nicolas LEDUC, Brigitte LUCAS, Dominique MILLE, Hanifa AMMARGUELLAT, Abeer NAJEM, Fanny TROUBOUL, Philippe BARTHELEMY, Hervé DESCLOS, Didier MAYEUR, Fabrice LORCHEL, François GUINET, Anne-Pascale LAURENTY, Axelle BOUDRANT, Olivier GISSEROT, Corinne ALLEAUME, Aimery DE GRAMONT
Publikováno v:
Lancet Oncology
Lancet Oncology, 2022, 23 (11), pp.1367-1377. ⟨10.1016/S1470-2045(22)00555-1⟩
Lancet Oncology, 2022, 23 (11), pp.1367-1377. ⟨10.1016/S1470-2045(22)00555-1⟩
In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an
Autor:
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amélie Anota, Alicja Puszkiel, Anne Floquet, Hélène Vegas, Hugues Bourgeois, Leïla Bengrine Lefevre, Benoît You, Fanny Pommeret, Alain Lortholary, Dominique Spaeth, Anne-Claire Hardy-Bessard, Cyril Abdeddaim, Marie-Christine Kaminsky-Forrett, Michel Tod, Jean-Emmanuel Kurtz, Francesco Del Piano, Jérôme Meunier, Nadia Raban, Jérome Alexandre, Marie-Ange Mouret-Reynier, Isabelle Ray-Coquard, Magali Provansal Gross, Pierre-Emmanuel Brachet
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab.In the randomized phase II TAPAZ trial
Autor:
Patricia Pautier, Laurence Gladieff, Pierre-Etienne Heudel, Jérôme Meunier, Yousef Tazi, Frédéric Selle, Dominique Spaeth, Dominique Berton, Nathalie Bonichon-Lamichhane, Magali Provansal, Elsa Kalbacher, Jean-Pierre Lotz, Paule Augereau, Astrid Pozet, H. Orfeuvre, Anne-Claire Hardy-Bessard
Publikováno v:
Anticancer Research. 40:3939-3945
Background Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventio
Autor:
François-Clément Bidard, Jean-Yves Pierga, Thomas Bachelot, Jean-Luc Canon, Céline Callens, Isabelle Moullet, Frédérique Berger, Luis Augusto Teixeira, Ivan Bièche, Barbara Pistilli, Dominique Spaeth, Sibille Everhard, Suzette Delaloge, Florian Clatot, Hélène Vegas, Florence Dalenc, Jérôme Lemonnier, Anne Pradines, Thibault De La Motte Rouge, Jean-François Paitel, Véronique D'Hondt
Publikováno v:
Cancer Research. 80:P5-11
Background: In ER+ HER2- metastatic breast cancer (MBC), activating ESR1 mutations (ESR1mut) confer resistance to aromatase inhibitors (AI) when used as single agent. The impact of ESR1mut, when detected at baseline (prior to the initiation of therap
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Masitinib (MAS) is an oral, small molecule drug that targets mast cell and macrophage activity. These innate immune cells are critical components of the tumor microenviro...
Autor:
Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche
Publikováno v:
Cancers
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc71b63af8c9862b6ab08fc449cfdcd5
https://hal.inrae.fr/hal-03332168
https://hal.inrae.fr/hal-03332168